Veeva Link Now Available for 12 Therapeutic Areas Across More Than 50 Countries
Veeva Systems announced the addition of 11 new therapeutic areas to its customer intelligence platform, Veeva Link, now covering 12 areas including oncology. The platform provides curated expert profiles and real-time insights to enhance engagement between life sciences teams and global experts. Key areas expanded include cardiology, neurology, and respiratory diseases. Veeva aims to set the industry standard in real-time customer intelligence, supporting better research and patient care. A summit on June 10, 2021, will showcase how Veeva Link aids pharma companies in personalizing customer interactions.
- Expansion of Veeva Link to 12 therapeutic areas enhances market reach.
- Improved real-time insights and engagement capabilities for customer interactions.
- Support from pharmaceutical companies using Veeva Link for personalized strategies.
- None.
PLEASANTON, Calif., June 9, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of 11 new therapeutic areas in the Veeva Link customer intelligence platform. Initially started in oncology, Veeva Link delivers deep, curated expert profiles with real-time insights that help life sciences teams find and engage with global experts across twelve therapeutic areas.
"Veeva Link allows us to transform customer engagement by better connecting with key people, understanding the ecosystem around them, and making every interaction more relevant," said Gandolf Finke, CEO at Fosanis. "Partnering with Veeva will help us bring our life-changing digital solutions to patients."
Veeva Link delivers detailed information on key people — such as their expertise, collaborations, and scientific and digital activities. Dynamic profiles are sourced from thousands of publicly available data sources, including social media feeds, publications, clinical trials, events, and associations.
The expanded Veeva Link offering provides accurate and relevant data on influential stakeholders in bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology, in addition to its existing oncology solution.
"With our expansion to new therapeutic areas and the depth of our profiles, Veeva Link is setting the industry standard for real-time customer intelligence," said Kilian Weiss, general manager for Veeva Link at Veeva Systems. "By tapping into a broad range of digital and scientific data sources and embedding these insights into Veeva's Commercial Cloud, we are helping the healthcare community improve research and patient care."
For more information on Veeva Link and the new therapeutic areas, join the Veeva Commercial & Medical North America Summit Connect on June 10, 2021. The live online event will feature sessions from top 20 pharmaceutical companies discussing how customer insights from Veeva Link are helping them drive more agile, personalized interactions and build stronger relationships, as well as from a rapidly growing biotech about using market-level insights to accelerate its first product launch. Life sciences industry professionals can learn more and register at veeva.com/Summit.
Additional Information
For more on Veeva Link, visit: veeva.com/veeva-link
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended April 30, 2021. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
Contact:
Meagan Busath
Veeva Systems
925-452-6500
meagan.busath@veeva.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/veeva-link-now-available-for-12-therapeutic-areas-across-more-than-50-countries-301309204.html
SOURCE Veeva Systems
FAQ
What new therapeutic areas has Veeva introduced in Veeva Link?
When is the Veeva Commercial & Medical North America Summit Connect?
What is the significance of Veeva Link's expansion?
What is the stock symbol for Veeva Systems?
How does Veeva Link support the life sciences industry?
